Alison Armour
Corporate Officer/Principal bij Royal College of Physicians & Surgeons of Glasgow
Profiel
Momenteel bekleedt Alison A. Armour de functie van Senior Vice President-Research & Development bij Halozyme Therapeutics, Inc. Dr. Armour is ook lid van het Royal College of Physicians & Surgeons of Glasgow. Dr. Armour was voorheen Vice President-Oncology bij GlaxoSmithKline Plc, Vice President-Oncology bij Novartis AG en Chief Medical Officer van Endocyte, Inc. (een dochteronderneming van Novartis AG) en Director-Global Medical Science bij AstraZeneca Plc. Alison A. Armour behaalde een doctoraal, een doctoraal en een doctoraat aan de Universiteit van Glasgow.
Actieve functies van Alison Armour
Bedrijven | Functie | Begin |
---|---|---|
Royal College of Physicians & Surgeons of Glasgow
Royal College of Physicians & Surgeons of Glasgow Other Consumer ServicesConsumer Services The Royal College of Physicians and Surgeons of Glasgow is a multidisciplinary organization that sets standards of care for the prevention and treatment of sickness and trauma in travelers. The British company has published a good practice guide for providing a travel health service, which defines the standards of care every practitioner should achieve in their practice of travel medicine for the health and safety of the international traveler. The organization offers a wide range of membership benefits and discounts on clinical and non-clinical skills courses, conferences, and e-learning. The private company also provides examinations and assessments across medical, surgical, and dental specialties to advance the profession and improve patient care through continuing professional development. | Corporate Officer/Principal | - |
Eerdere bekende functies van Alison Armour
Bedrijven | Functie | Einde |
---|---|---|
HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01-01-2020 |
NOVARTIS AG | Corporate Officer/Principal | 01-07-2015 |
GSK PLC | Corporate Officer/Principal | 01-07-2015 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01-08-2011 |
ENDOCYTE, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Alison Armour
University of Glasgow | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
ASTRAZENECA PLC | Health Technology |
HALOZYME THERAPEUTICS, INC. | Health Technology |
NOVARTIS AG | Health Technology |
GSK PLC | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Endocyte, Inc.
Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Royal College of Physicians & Surgeons of Glasgow
Royal College of Physicians & Surgeons of Glasgow Other Consumer ServicesConsumer Services The Royal College of Physicians and Surgeons of Glasgow is a multidisciplinary organization that sets standards of care for the prevention and treatment of sickness and trauma in travelers. The British company has published a good practice guide for providing a travel health service, which defines the standards of care every practitioner should achieve in their practice of travel medicine for the health and safety of the international traveler. The organization offers a wide range of membership benefits and discounts on clinical and non-clinical skills courses, conferences, and e-learning. The private company also provides examinations and assessments across medical, surgical, and dental specialties to advance the profession and improve patient care through continuing professional development. | Consumer Services |